// App-Quantinova.ai

PB0652 : The Effect of DOAC-Stop® on Several Oral and Parenteral Anticoagulants

Researchers

Presenter

  • N. Riva

Principal Investigators

  • K. Vella

  • K. Hickey

  • P. Gatt

  • C. Grima

  • D. Zammit

  • S. Kitchen

  • M. Makris

  • W. Ageno

  • A. Gatt

Medical Centers

  • University of Malta, Department of Pathology, Faculty of Medicine and Surgery, Msida, Malta

  • Mater Dei Hospital, Coagulation Medicine Laboratory, Department of Pathology, Msida, Malta

  • University of Sheffield, Sheffield Haemostasis and Thrombosis Centre, Sheffield, United Kingdom

  • Mater Dei Hospital, Clinical Perfusion Services, Msida, Malta

  • University of Insubria, Department of Medicine and Surgery, Varese, Italy

Locations

  • Malta

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • Catalase

  • Activated partial thromboplastin time

Drug/Treatment

  • Fondaparinux sodium

  • rivaroxaban

  • Enoxaparin

  • Enoxaparin sodium

  • Pradax

  • Hydroxyzine

  • apixaban

  • Edoxaban

  • Evithrom

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved